CoChat

Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis

Open access
Beraza, Naiara, Ofner-Ziegenfuss, Lisa, Ehedego, Haksier, Boekschoten, Mark, Bischoff, Stephan C, Mueller, Michael, Trauner, Michael, Trautwein, Christian · 2011 · Gut
Cited by 47

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Hepatocyte-specific NEMO/NF-κB deleted mice (NEMO Δhepa ) develop spontaneous non-alcoholic steatohepatitis (NASH). Free fatty acids and bile acids promote DR5 expression. TRAIL/NK cell-mediated activation of TRAIL-R2/DR5 plays an important role during acute injury in NEMO Δhepa mice. Aim: To inhibit the progression of NASH in the absence of hepatocyte-NEMO/NF-kB signaling. Methods: NEMOf/f and NEMO Δhepa mice were fed with a low-fat diet, and with two anticholestatic diets; UDCA and NorUDCA. The impact of these treatments on the progression of NASH was evaluated. Results: We show that high expression of DR5 in livers from NEMO Δhepa mice is accompanied by an abundant presence of bile acids (BAs), misregulation of BA transporters and significant alteration of lipid metabolism-related genes. Additionally, mice lacking NEMO in hepatocytes spontaneously showed ductular response at young age. Unexpectedly, feeding of NEMO Δhepa mice with low-fat diet failed to improve chronic liver injury. Conversely, anti-cholestatic treatment with nor-ursodeoxycholic acid (NorUDCA), but not with ursodeoxycholic acid (UDCA), led to a significant attenuation of liver damage in NEMO Δhepa mice. The strong therapeutic effect of NorUDCA relied on a significant downregulation of LXR-dependent lipogenesis and the normalisation of BA metabolism through mechanisms involving cross-talk between Cyp7a1 and SHP. This was associated with the significant improvement of liver histology, NEMO Δhepa /NorUDCA-treated mice showed lower apoptosis and reduced CyclinD1 expression, indicating attenuation of the compensatory proliferative response to hepatocellular damage. Finally, fibrosis and ductular reaction markers were significantly reduced in NorUDCA-treated NEMO Δhepa mice. Conclusions: Overall, our work demonstrates the contribution of bile acids metabolism to the progression of NASH in the absence of hepatocyte-NF-kB through mechanisms involving DR5-apoptosis, inflammation and fibrosis. Our work suggests a potential therapeutic effect of NorUDCA in attenuating the progression of NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2010.223834

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 47

Metadata

Authors
Beraza, N., Ofner-Ziegenfuss, L., Ehedego, H., Boekschoten, M., Bischoff, S. C., Mueller, M., Trauner, M., & Trautwein, C.
Venue
Gut
Publisher
BMJ
Published
2010-11-29
Volume
60
Issue
3
Pages
387-396
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2169338378
Cited by
47
References
2
FWCI
1.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. https://app.cochat.ai/papers/10.1136/gut.2010.223834
The paper
Beraza, N., Ofner-Ziegenfuss, L., Ehedego, H., Boekschoten, M., Bischoff, S. C., Mueller, M., Trauner, M., & Trautwein, C. (2011). Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut. https://doi.org/10.1136/gut.2010.223834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.